Teleflex Q1 Earnings Beat, '25 EPS View Down, Stock Up

Core Insights - Teleflex Incorporated (TFX) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.91, a decrease of 9.3% year-over-year, but exceeded the Zacks Consensus Estimate by 1% [1] - The company's net revenues fell 5% year-over-year to $700.7 million, surpassing the Zacks Consensus Estimate by 0.2% [2] Revenue Breakdown - Revenues in the Americas segment were $475.7 million, down 3.7% year-over-year [3] - EMEA segment revenues decreased 5.3% year-over-year to $151.2 million [3] - Asia segment revenues fell 12.8% to $73.8 million [4] Product Revenue Performance - Vascular Access segment revenues increased by 1.9% year-over-year to $182.4 million [5] - Interventional business revenues rose 3.2% year-over-year to $137.5 million [5] - Anesthesia segment revenues decreased 8.6% year-over-year to $86.6 million [6] - Surgical segment revenues increased by 2% year-over-year to $105.8 million [6] - Interventional Urology segment revenues fell 10.7% year-over-year to $71 million [6] - OEM revenues decreased by 26.8% year-over-year to $63.9 million [7] - Other product segment revenues increased by 4.5% year-over-year to $53.5 million [7] Margin and Profitability - Gross profit was $389.4 million, down 6.4% year-over-year, with a gross margin of 55.6%, a contraction of 82 basis points [8] - Adjusted operating profit was $130.3 million, down 4.2% year-over-year, but the adjusted operating margin expanded by 17 basis points to 18.6% [9] Liquidity and Cash Flow - Teleflex ended Q1 2025 with cash and cash equivalents of $284.1 million, down from $290.2 million at the end of Q4 2024 [10] - Net cash flow from operating activities was $73.3 million, compared to $112.8 million in the prior year [11] Updated Guidance - The company now expects GAAP revenue growth for 2025 to be in the range of 1.28-2.28%, revised from a prior guidance of a decline of 0.4% to growth of 0.7% [12] - Adjusted EPS guidance for 2025 is now projected to be between $13.20 and $13.60, down from the previous range of $13.95 to $14.35 [12] Strategic Developments - Teleflex has entered into an agreement to acquire the Vascular Intervention business of BIOTRONIK SE & Co. KG, which will enhance its product portfolio and market presence [15] - The acquisition includes a range of vascular intervention devices, positioning the company for continued growth [15]